Randall G. Rupp
Keine laufenden Positionen mehr
Profil
Randall G.
Rupp served as Director-Cell Biology at Damon Biotech, Inc. He then worked at Regeneron Pharmaceuticals, Inc. for 17 years, where he held the position of Senior Vice President-Manufacturing Operations.
After leaving Regeneron, he worked as Vice President-Manufacturing & Development at Noveome Biotherapeutics, Inc. and as Vice President-Research & Development at BioHybrid Technologies, Inc. Rupp holds a doctorate degree from The University of Texas at Austin.
Ehemalige bekannte Positionen von Randall G. Rupp
| Unternehmen | Position | Ende |
|---|---|---|
| REGENERON PHARMACEUTICALS, INC. | Corporate Officer/Principal | 02.04.2008 |
| Damon Biotech, Inc. | Corporate Officer/Principal | - |
| BioHybrid Technologies, Inc. | Technik-/Wissenschafts-/F&E-Leiter | - |
Noveome Biotherapeutics, Inc.
 Noveome Biotherapeutics, Inc. BiotechnologyHealth Technology Noveome Biotherapeutics, Inc. develops novel biotherapeutic products that restore cell communication and system homeostasis. Its proprietary technology platform, derived from human placental cells, provides an exciting new approach to tissue regeneration and repair in a wide range of medical conditions and offers hope, especially in patients with maladies. The company was founded in 2001 by George L. Sing and William J. Golden and is headquartered in Pittsburgh, PA. | Corporate Officer/Principal | - |
Ausbildung von Randall G. Rupp
| The University of Texas at Austin | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| REGENERON PHARMACEUTICALS, INC. | Health Technology |
| Private Unternehmen | 3 |
|---|---|
| Damon Biotech, Inc. | Health Technology |
Noveome Biotherapeutics, Inc.
Noveome Biotherapeutics, Inc. BiotechnologyHealth Technology Noveome Biotherapeutics, Inc. develops novel biotherapeutic products that restore cell communication and system homeostasis. Its proprietary technology platform, derived from human placental cells, provides an exciting new approach to tissue regeneration and repair in a wide range of medical conditions and offers hope, especially in patients with maladies. The company was founded in 2001 by George L. Sing and William J. Golden and is headquartered in Pittsburgh, PA. | Health Technology |
| BioHybrid Technologies, Inc. |
